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Background and Objectives
Mantle cell lymphoma (MCL), a mature B-cell neoplasm, is genetically characterized
by the translocation t(11;14)(q13;q32). However, secondary alterations are required
for malignant transformation. The identification of inactivated tumor suppressor
genes contributing to the development of MCL may lead to further elucidation of the
biology of this disease and help to identify novel targets for therapy.
Design and Methods
Whole genome microarray-based gene expression profiling on treated versus untreat-
ed MCL cell lines was used to identify genes induced by 5-aza-2’-deoxycytidine. The
degree of promoter methylation and transcriptional silencing of selected genes was
then proven in MCL cell lines and primary cases by methylation-specific polymerase
chain reaction (PCR) techniques, real-time PCR and gene expression profiling.
Results
After 5-aza-2’-deoxycytidine treatment, we identified more than 1000 upregulated
genes, 16 of which were upregulated ≥3-fold. Most of them were not known to be
silenced by methylation in MCL. A low expression of ING1, RUNX3 and BNIP3L was
observed in three of the five the MCL cell lines. In addition, the expression of PARG1,
which is located in the frequently deleted region 1p22.1, was substantially reduced
and displayed at least partial promoter methylation in all investigated MCL cell lines
as well as in 31 primary MCL cases. 
Interpretation and Conclusions
In summary, we identified interesting novel candidate genes that probably contribute
to the progression of MCL and suggest that PARG1 is a strong candidate tumor sup-
pressor gene in MCL. 
Key words: mantle cell lymphoma, epigenetic silencing, tumor suppressor gene,
PTPL1-associated RhoGAP1 (PARG1).
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In the current World Health Organization classificationof tumors, mantle cell lymphoma (MCL) is defined asa distinct subtype of the mature B-cell neoplasms and
comprises approximately 3-10% of non-Hodgkin’s lym-
phomas.1 Clinically, MCL is characterized by an aggres-
sive disease course and a poor prognosis with a median
survival of 3 years and only 10-15% long-term survivors.2
The genetic hallmark of MCL is the translocation
t(11;14)(q13;q32), which is present in virtually all cases3,4
and causes overexpression of cyclin D1.5,6 However, there
is experimental evidence indicating that additional alter-
ations are required to induce lymphoma genesis.7
Classical cytogenetic and comparative genomic
hybridization (CGH) studies have shown a high number
of recurrent chromosomal alterations in t(11;14)-positive
MCL.8-10 Loss of the chromosomal fragment 11q22-23 har-
boring the ataxia-telangiectasia mutated (ATM) gene is
observed in almost 50% of MCL.11,12 However, in many
other regions of genomic loss, the putative tumor sup-
pressor genes have not been identified. 
Today, it is widely accepted that, in addition to inacti-
vation of a tumor suppressor gene by deletion and muta-
tion, DNA hypermethylation of promoter CpG islands
represents a third mode to satisfy Knudson’s hypothesis.13
Although tumor cell lines may display a greater extent of
CpG island hypermethylation than the primary tumors,
they still carry the characteristic aberrant methylation
modifications14 and could therefore be used as methylo-
type models of the primary tumors.15
To search for novel candidate genes probably involved
in the progression of t(11;14)-positive MCL, we treated
the human MCL cell line Granta-51916,17 with 5-aza-2’-
deoxycytidine (5-aza-CdR) to identify epigenetically
silenced genes. This inactivating substrate of DNA
methyltransferase18 induces an indirect genomic
demethylation19 and chromatin remodeling20 and can,
therefore, lead to the reactivation of transcriptionally
silenced genes.21 We identified upregulated genes by
means of cDNA microarray analysis in a similar manner
to that used in recent reports.22-26 The selection of poten-
tial candidate genes from the list of reexpressed genes
was based on their location in frequently deleted regions,
and their relevance in regulation of proliferation, apopto-
sis or DNA repair. ATM, ING1, PARG1, RUNX3, BNIP3L,
PUMA, JUNB, CCNA1, CXCL10, CXCL9 were selected
for further investigations in five t(11;14)-positive MCL
cell lines. PARG1 was identified as a strong candidate
tumor suppressor gene on 1p22.1 and was subsequently
investigated in primary MCL samples.
Design and Methods
Cell culture and 5-aza-CdR treatment
The Granta-519 and Jvm-2 cell lines were received from
H.G. Drexler (DSMZ, Braunschweig, Germany), NCEB-1
and JeKo-1 were obtained from M. Daibata (Kochi
Medical School, Kochi, Japan) and HBL-2 was obtained
from M. Abe (Fukushima Medical College, Fukushima,
Japan). All cell lines were cultured in RPMI 1640 supple-
mented with 10% heat inactivated fetal bovine serum,
100 U/mL penicillin, 100 µg/mL streptomycin, and addi-
tional 4 mM N-acetyl-L-alanyl-L-glutamine (all from
Biochrom, Berlin, Germany). For treatments, Granta-519
cells were incubated with 0.01, 0.1 and 0.5 µM 5-aza-CdR
(Fluka, Seelze, Germany) dissolved in 0.1% DMSO. A
solvent control was simultaneously incubated with 0.1%
DMSO. All treatment experiments were performed using
extensively characterized Granta-519 cells in the expo-
nentially growing phase.17
Patients’ samples
In total, 31 MCL samples were analyzed. In most cases
the origin of the analyzed tissue was lymph node, except
for one spleen (sample 6), three bone marrow (sample 4)
and one blood sample. In all patients, the diagnosis of
MCL was confirmed by histology and immunopheno-
type. Except for one blastoid MCL all cases were classical
MCL. Informed consent was provided according to the
Declaration of Helsinki.
DNA extraction
DNA from bone marrow, blood and cell cultures was
extracted using the DNA Isolation Kit for Mammalian
Blood (Roche, Mannheim, Germany). When extracting
DNA from cell lines the step of red cell lysis was omitted.
DNA from MCL frozen sections was extracted according
to standard procedures with proteinase K digestion and
sodium chloride precipitation. The DNA was further
purified using the QIAamp DNA mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s proto-
col.
Isolation of CD19+ peripheral blood mononuclear cells
(PBMC)
PBMC from healthy donors (n=5) were separated by
density gradient centrifugation using Leucosep tubes
(Greiner bio-one, Solingen-Wald, Germany) and Ficoll
paque PLUS solution (Amersham Biosciences, Freiburg,
Germany). To isolate CD19+ PBMC, magnetic activated
cell sorting (MACS) CD19 microbeads and MACS separa-
tion columns (both from Miltenyi Biotec, Bergisch-
Gladbach, Germany) were used to perform immunomag-
netic bead selection according to the manufacturer’s pro-
tocol.
Western blotting 
Western blotting was performed using standard proce-
dures. Briefly, total protein extracts from harvested cells
(40 µg) were separated by 15% sodium dodecylsulfate
polyacrylamide gel electrophoresis and blotted on Roti-
polyvinylidene fluoride membranes (Roth, Karlsruhe,
Germany). The membrane was probed with different
antibodies and visualized with an enhanced chemilumi-
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nescence (ECL) detection kit (Amersham Biosciences,
Freiburg, Germany) in an LAS-1000 luminescence image
analyser (Fuji Photo Film Co., Tokyo, Japan). To test the
uniform loading of all lanes, membranes were probed
with a goat polyclonal antibody against actin. A goat
polyclonal antibody for actin (C-11, sc-1615, Santa Cruz
Biotechnology, Heidelberg, Germany), and a mouse mon-
oclonal antibody against 14-3-3σ (clone 1433S01,
Labvision-Neomarkers, Microm, Walldorf, Germany)
were used as primary antibodies. A horseradish peroxi-
dase-conjugated goat-anti-mouse (sc-2005, Santa Cruz
Biotechnology) or donkey-anti-goat (sc-2020, Santa Cruz
Biotechnology) antibody (both Santa Cruz
Biotechnology) was used as a secondary antibody.
cDNA microarray analysis
For cDNA microarray experiments Granta-519 cells
were treated with 0.1 µM 5-aza-CdR for 4 days in three
parallel experiments as described above. Total RNA was
isolated using Trizol Reagent (Invitrogen, Karlsruhe,
Germany) followed by RNeasy Mini Kit (Qiagen,
Hilden, Germany) and on-column DNase digestion
with RNase-free DNase I (Qiagen). One microgram of
total RNA was linearly amplified using a MessageAmp
aRNA kit (Ambion, Huntingdon, Cambridgeshire, UK).
Quantification and validation for integrity was per-
formed on an Agilent 2100 Bioanalyzer using an RNA
6000 NanoLabChip kit according to the manufacturer’s
protocol (Agilent Technologies, Böblingen, Germany).
Three micrograms each of amplified RNA from the 5-
aza-CdR treated cells (sample) and the solvent control
(reference) were labeled with Cy5-dUTP and Cy3-
dUTP (Amersham Biosciences), respectively. In each of
the three parallel experiments, fluorescence-labeled
RNA probes of the sample and the corresponding refer-
ence were comparatively hybridized on a spotted
cDNA microarray (Stanford Functional Genomics
Facility, Stanford, CA, USA) according to the posted
protocol (http://brownlab.Stanford.edu/protocols.html). The
fluorescence intensities of Cy5 and Cy3 were measured
on a GenePix 4000 scanner (Axon Instruments, Foster
City, CA, USA) and analyzed using GenePix Pro 4.1
software (Axon Instruments). Areas of the microarray
or spots exhibiting obvious damages due to technical
failures were excluded from subsequent analysis. Single
spots were only considered as well-measured and
included in the further investigation when the mean flu-
orescent intensity of Cy5 and Cy3 was ≥3-fold more
than the local background and the regression correlation
was ≥0.8. Genes were classified as upregulated when
the corresponding spot met these quality criteria and a
log (base 2) ratio of Cy5 relative to Cy3 revealed a value
of ≥0.3 in at least two of the three parallel experiments.
Quantitative real-time PCR for relative quantification
In a total volume of 120 µL, 1 µg total RNA was
reverse-transcribed by M-MuLV reverse transcriptase
using random hexamer primers (RevertAid First Strand
cDNA synthesis kit; Fermentas, St-Leon-Rot, Germany).
Two microliters of each cDNA sample were amplified
on an iCycler iQ real-time detection system (Bio-rad
Laboratories, München, Germany) using a QuantiTect
SYBR Green PCR kit (Qiagen, Hilden, Germany).
Melting curve analyses were performed to verify the
amplification specificity. Relative quantification of gene
expression was performed according to the ∆∆-CT
method27 using iCycler iQ real-time detection system
software version 3.1 (Bio-rad Laboratories). SDHA was
used as an internal control gene. Detailed PCR condi-
tions and primer sequences are listed as supplemental
data.
Bisulfite modification of genomic DNA
One microgram of DNA was denatured by NaOH
and modified by sodium bisulfite using the CpGenome
DNA modification kit (Intergen Company, Purchase,
NY, USA). The modified DNA was purified, treated
with NaOH to desulfonate, washed with ethanol and
finally resuspended in 30 µL TE buffer.
Methylation-specific polymerase chain reaction
(MSP)
The MSP technique used in the present study was
originally described by Herman et al.28 Two microliters
of the modified DNA samples were amplified. Detailed
PCR conditions and primer sequences are listed as sup-
plemental data. MSP products were analyzed on 3%
agarose gels or on an Agilent 2100 Bioanalyzer using a
DNA 1000 LabChip kit (Agilent Technologies) accord-
ing to the manufacturer’s protocol. 
Combined bisulfite restriction analysis (COBRA)
In order to carry out COBRA, a technique originally
described by Xiong and Laird,29 CpG islands were
defined using the CpG island searcher (http://www.usc-
norris.com/cpgislands2/cpg.aspx) according to the
revised criteria of Takai and Jones.30 For bisulfite-PCR, 2
µL of the modified DNA samples were amplified fol-
lowed by restriction digestion using the following
restriction enzymes: Hinf1, Mwo1 (HpyF10V1) and Taq1
(all purchased from Fermentas GmbH, St.Leon-Rot,
Germany). Restriction maps were designed using
Discovery Studio Gene version 1.5 (Accelrys Inc.,
Cambridge, UK). Detailed PCR conditions, primer
sequences and the position of investigated CpG islands
are listed as supplemental data.
Bisulfite sequencing
The PARG1 PCR product of 295 bp was generated as
described for COBRA. Fresh PCR products were cloned
into plasmids using the TOPO TA cloning Kit
(Invitrogen, Karlsruhe, Germany). Individual clones
were sequenced using the CEQ™ DTCS-Quick start Kit
(Beckman Coulter GmbH, Krefeld, Germany) with uni-
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versal T3 and T7 primers after amplification of the
insert with M13 forward and reverse primers. Sequence
reactions were analyzed using the CEQ 8000
Sequencing System (Beckman Coulter GmbH, Krefeld,
Germany).
Results
5-aza-CdR treatment of Granta-519 cells
To establish a demethylation protocol utilizing non-
cytotoxic doses of 5-aza-CdR on Granta-519 cells, the
cells were treated with 0.01, 0.1 or 0.5µM 5-aza-CdR
for up to 6 days. In line with the results of an earlier
study on the anti-tumor effect of 5-aza-CdR,31 time- and
dose-dependent inhibition of cell proliferation was seen
with a concomitant increase of G1-phase cells and a
decrease of S-phase cells. Possible induction of apopto-
sis or cytotoxicity could be excluded at all dose levels
examined, as ensured by negative propidium
iodide/annexin V double staining and identification of
normal levels of marker genes p53, p21, Bcl-2, Bax and
caspase-9 upon Western blotting (data not shown). Re-
expression of the 14-3-3σ gene, which is constitutively
methylated in the Granta-519 cell line (data not shown),
served as a functional control for successful demethyla-
tion (Figure 1).
cDNA microarray analysis
The microarray analysis displayed more than 1000
upregulated genes, 16 of which were upregulated ≥3-
fold. For further studies, upregulated genes that met the
quality criteria were selected according to the following
criteria (Table 1): (i) genes are located in chromosomal
regions that are frequently deleted in MCL: ATM, ING1,
PARG1 and RUNX3;32-34 (ii) genes which code for pro-
apoptotic members of the Bcl-2 family: BNIP3L and
PUMA; (iii) JUNB, for which transcriptional silencing
was reported in hematologic malignancies;35 and (iv) the
top three upregulated genes: CCNA1, CXCL10 and
CXCL9. 
Quantitative real-time PCR analysis in untreated
t(11;14)-positive cell lines
To determine whether identified candidate genes are
down-regulated by transcriptional silencing, their
expression was evaluated by quantitative real-time PCR
analysis in untreated t(11;14)-positive cell lines Granta-
519, Hbl-2, Jvm-2, JeKo-1 and NCEB-1. Using the ∆∆-
CT method27 and succinate dehydrogenase complex,
subunit A, flavoprotein (SDHA) as an internal control,
relative quantification was performed. The expression
level in CD19+ PBMC obtained from five healthy
donors was set as 1 (Figure 2). The expression of ATM,
ING1 and PARG1 was reduced in all studied cell lines
(Figure 2A-C). The expression of RUNX3 was clearly
reduced in three of five cell lines (Figure 2D). Studying
the selected pro-apoptotic genes of the Bcl-2 family,
BNIP3L was downregulated in all t(11;14)-positive cell
lines except in JeKo-1 (Figure 2E). A distinct reduction of
PUMA expression was seen in Hbl-2, JeKo-1 and NCEB-
1 (Figure 2F). The expression of JUNB was only reduced
in HBL-2 and JeKo-1 (data not shown). Interestingly, none
of the most highly upregulated genes (Table 1D) was
Table 1. List of investigated genes. Upregulated genes were select-
ed for further investigations according to their putative function in
tumorigenesis. The displayed x-fold upregulation represents the
mean value of triplicate determinations.
Gene Cytoband x-fold x-fold
upregulated upregulated
on microarray in real time PCR
A upregulated genes from frequently lost sites
ATM 11q22-q23 1.5 1.9
ING1 13q34 1.5 1.7
PARG1 1p22.1 1.9 3.3
RUNX3 1p36 1.9 7.1
B upregulated pro-apoptotic BCL2-family members  
BNIP3L 8p21 1.8 8.1
PUMA 19q13.3-q13.4 2.1 9.3
C reported methylation in haematologic malignancies 
JUNB 19p13.2 1.7 4.7
D highly upregulated genes with discussed cancer connection 
CCNA1 13q12.3-q13 6.4 71.8
CXCL10 4q21 8.9 25.2
CXCL9 4q21 7.2 57.0
Figure 1. Reactivation of 14-3-3σ in Granta-519. Cells treated with
different doses of 5-aza-CdR for 2 and 4 days. Data are representa-
tive of one of two independent experiments. Solvent control (lanes
1 and 5), 0.01 µM (lanes 2 and 6), 0.1 µM (lanes 3 and 7), 0.5 µM
(lanes 4 and 8) 5-aza-CdR. (A) Methylation-specific PCR (Agilent
analysis. M: methylation-specific primers, U: unmethylation-specific
primers). (B) Quantification of 14-3-3σ expression in 5-aza-CdR
treated cells relative to the cells treated with solvent control using
real-time PCR and the ∆∆-CT method. (C) Western blotting. 
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downregulated in untreated MCL cell lines. Since this
seems to be attributable to demethylation-independent
influences of 5-aza-CdR, secondary changes and/or the
reactivation of endogenous retroviruses or retroviral ele-
ments,22-24,26,36,37 none of these genes was investigated fur-
ther. 
Methylation analyses
To investigate the methylation of promoter CpG
islands, ATM, RUNX3 and JUNB were analyzed by MSP
and ING1, PARG1 and BNIP3L by COBRA. Methylated
alleles of ATM were distinctly amplified in four of five
t(11;14)-positive cell lines, whereas in CD19+ PBMC and
Hbl-2 only a slight band indicating the methylated state of
DNA was observed (Figure 3A). In contrast, RUNX3
showed constitutive methylation in all investigated cell
lines and in CD19+ PBMC (Figure 3B). No methylation of
the JUNB promoter site was found (Figure 3C). 
Performing COBRA, restriction digestion demonstrates
the methylation of the investigated CpG site. Thus, partial
and full digestion indicate incomplete and complete
methylation, respectively, and no digestion corresponds to
an unmethylated state. Analyses of ING1 showed no evi-
Figure 2 (left). Relative quantification of gene expression in
untreated t(11;14)-positive cell line. The expression of selected
genes in t(11;14)-positive cell lines was quantified relative to the
expression in CD19+ PBMC of healthy donors using real time PCR
and the ∆∆-CT method. The expression level in the CD19+ PBMC
of healthy donors was set as 1. The displayed columns represent
the mean value and standard deviation of triplicate determina-
tions. A, ATM. B, ING1. C, PARG1. D, RUNX3. E, BNIP3L and F,
PUMA. (n.e. – no expression was detected in the real-time PCR).
Figure 3. MSP in t(11;14)-positive MCL cell lines and CD19+
PBMC. To confirm epigenetic changes in the t(11;14)-positive MCL
cell lines in comparison to CD19+ PBMC from healthy donors, MSP
was performed (M: methylation-specific primers, U: unmethyla-
tion-specific primers) (A), ATM. (B) RUNX3. (C) JUNB.
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dence of methylation (Figure 4A). COBRA of PARG1 in
CD19+ PBMC did not show any methylation, since there
was no digestion of the PCR product (295 bp) leading to
the expected fragment of 212 bp by Mwo1 in the case of
methylation. In contrast, full methylation was found in
Granta-519, Hbl-2 and JeKo-1 cells. Partial methylation
was demonstrated in Jvm-2 and NCEB-1 (Figure 4B).
Finally, investigations of BNIP3L displayed a complete
digestion of the PCR product (530bp) by Taq1 that leads to
a fragment of 212 bp in all studied cell lines as well as in
the investigated CD19+ PBMC (Figure 4C).
Methylation in primary MCL samples
To investigate further whether PARG1 is a candidate
tumor suppressor gene, inactivated in MCL by methyla-
tion, 31 primary MCL samples were analyzed by COBRA
and bisulfite sequencing. The PCR products (295 bp)
obtained from bisulfite converted DNA of all samples
were at least partially digested by Hinf1 that leads to the
expected fragments of 181bp and 114bp (Figure 5). Finally,
promoter methylation of PARG1 in primary tumor sam-
ples was confirmed by bisulfite sequencing (Figure 5). In
conclusion, clear differences between the control CD19+
PBMC and the t(11;14)-positive MCL cell lines as well as
the primary tumor cells regarding promoter methylation
were demonstrated for PARG1, which is located in the fre-
quently deleted chromosomal region 1p22.1.
PARG1 expression in primary tumor cells
Finally, we sought to determine whether aberrant
methylation of the PARG1 promoter leads to reduced
expression of the PARG1 gene in primary tumor cells.
Expression data for PARG1 were obtained from a gene
expression profiling analysis of primary MCL cases that
was performed on the GeneCHIP Human Genome
U133 Plus 2.0 Array (Affymetrix, Santa Clara, USA)
(Schraders, M. et al., submitted). Since the tumor load was
more than 90%, microdissection was not necessary.
Comparing PARG1 expression in control cells, using
cells from lymph nodes with follicular hyperplasia, with
the expression in MCL cells, a significant down-regula-
tion could be demonstrated in the tumor cells (Figure
5D). 
Discussion
To screen for epigenetic aberrations in MCL, we com-
bined a cDNA microarray approach with non-cytotox-
ic, demethylating 5-aza-CdR treatment of Granta-519,
the most frequently used MCL cell line. From the upreg-
ulated genes with putative function in MCL tumorigen-
esis, we selected ten candidate genes for further investi-
gations in five untreated t(11;14)-positive cell lines, to
validate whether these genes are indeed transcriptional-
ly downregulated and methylated in MCL.
Because epigenetic changes can co-operate with
genetic aberrations, leading to the inactivation of tumor
suppressor genes,13 we focused on the expression level
of the genes located in frequently deleted chromosomal
regions in MCL (Table 1A).32-34 Real time PCR confirmed
the findings of the microarray analyses for all ten genes.
However, the observed upregulation may occur not
only through demethylation of otherwise methylated
promoter regions but also due to other transcriptional or
translational regulation or activation of retroviral ele-
ments.22-24,26,36,37 Therefore, it is essential to determine the
extent of methylation of the promoter regions of these
genes directly. For this purpose, bisulfite DNA modifica-
tion was applied. This treatment leads to a conversion
of unmethylated but not methylated cytosines to
uracils. Subsequently, MSP or COBRA was carried out
for interesting genes in the five untreated t(11;14)-posi-
tive cell lines. Moreover, the extent of gene methylation
in MCL cell lines was compared with that of the normal
counterpart, CD19+ B cells from healthy donors. No
promoter methylation of JUNB and ING1 was found.
Also, no differential methylation was seen for RUNX3
and BNIP3L, which were equally methylated both in
control B cells and in MCL cell lines. In contrast, ATM
and PARG1 were at least partially methylated in the
MCL cell lines, but only slightly or completely
unmethylated in the control B cells, respectively.
ATM, which plays a key role in DNA repair and G2/S
checkpoint control, is frequently inactivated by dele-
tions and point mutations in MCL.11,12,32,33,38-41 Patients
Figure 4. COBRA in t(11;14)-positive MCL cell lines and CD19+
PBMC. In consideration of the known demethylation-independent
effects of 5-aza-CdR, selected genes were investigated by COBRA,
to test for epigenetic changes in the t(11;14)-positive cell lines in
comparison to CD19+ PBMC from healthy donors. To control the
restriction enzyme digestion, the PCR-product of a PCR, in which
non-bisulfite-converted DNA was amplified, was simultaneously
digested with the indicated restriction enzyme and is shown as
control. (A) ING1. (B) PARG1 and (C) BNIP3L.
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B
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Granta-519 HbL-2 Jvm-2 JeKo-1 NCEB-1 CD19+ H2O control
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Granta-519 HbL-2 Jvm-2 JeKo-1 NCEB-1 CD19+ H2O control
Granta-519 HbL-2 Jvm-2 JeKo-1 NCEB-1 CD19+ H2O control
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310 bp
205 bp
156 bp
437 bp
control
437 bp
310 bp
295 bp
212 bp
530 bp
212 bp
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with chronic lymphocytic leukemias (CLL) with dele-
tions of 11q, involving the ATM locus, have a signifi-
cantly poorer prognosis than other CLL patients.42 So
far, there is only one study about epigenetic mecha-
nisms leading to the inactivation of ATM in MCL show-
ing the absence of ATM hypermethylation in eight pri-
mary cases as well as in Granta-519 cells.43 The discrep-
ancy between these and our results may be explained
by the fact that although the identical promoter region
was analyzed (position -4578 to -4799 on the genomic
level based on the ATM transcription start site), different
primers, leading to a larger PCR fragment, were used.
Since methylation of a tumor suppressor gene does not
mean that each CpG site is methylated and that methy-
lation is 100% at each site, primer design has a big
impact on the results.44 However, the ATM gene is a tar-
get for epigenetic silencing in advanced breast cancer,45
head and neck cancer46 and colorectal cancer.47 Future
studies will have to clarify whether promoter methyla-
tion, which was shown in four of the five cell lines for
the first time, induces relevant inactivation of ATM in
patients with MCL and CLL and whether it is associat-
ed with the clinical outcome. 
PARG1 codes for PTPL1-associated RhoGAP1, a
GTPase-activating protein (GAP) that exhibits in vitro
GAP activity towards the Rho- and Ras-family mem-
bers Rho48 and Rap2,49 thus promoting a switch from the
active to the inactive form50 and that may, therefore, act
as a suppressor of Rho- and Ras-mediated cellular trans-
formation.50 Recently, Ghobrial and co-workers report-
ed on the overexpression of the guanine nucleotide
exchange factor RCC1 (regulator of chromosome con-
densation 1) and the RhoA-dependent kinase CRIK (cit-
ron Rho-interacting kinase) in MCL, suggesting that
Figure 5. COBRA and bisulfite sequencing of PARG1 in primary MCL samples. (A) A section (-692 to +90) of a CpG island in the 5’ region
of PARG1 (-692 to +777) with the location of the COBRA PCR product (-435 to - 140) near the transcription start site (TS) is shown.
Vertical lines indicate individual CpG sites. The dark gray box represents exon 1. (B) COBRA on 19 primary MCL samples. Restriction
digestion of the 295 bp PCR fragment with Hinf1 leads to products of 181 bp and 114 bp indicating at least partial methylation in all
cases. (C) Bisulfite sequencing results of the converted antisense strand of a selected tumor sample showing strong methylation (No.
5) and CD19+ PBMC. The original sequence (-175 to -270), with CpG islands indicated by gray boxes, is shown above the electrophero-
grams. Methylated CpG sites are indicated by arrows. (D) PARG1 gene expression (pool of six control lymph nodes with follicular hyper-
plasia– gray, MCL without 1p loss (mean values of five cases) – light red, MCL with 1p loss (mean values of six cases) – dark red):
GeneCHIP Human Genome U133 Plus 2.0 Array contains four probes for PARG1 (Locus Link 9411). Three probes were not informative
because there was no expression at all in either MCL cases with or without 1p loss or in controls (1554736_at, 1558280_s_at,
1560318_at). Probe 203910_at showed a much lower expression in primary MCL than in controls.
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alterations of the Rho-Ras-network may be involved in
the pathogenesis of MCL.51 Moreover, PARG1 is located
in 1p22.1, one of the most frequently deleted regions in
MCL.32 In this respect, attention should be paid to the
observation that array-CGH revealed a monoallelic
deletion in Granta-519 and JeKo-1.34 In addition to this
allelic loss, our studies demonstrated a downregulation
and full methylation of PARG1 in these t(11;14)-positive
MCL cell lines. The other MCL cell lines also showed
downregulation due to full or partial methylation.
Finally, methylation of PARG1 was demonstrated in 31
primary MCL samples. Two of the cases were also
investigated by array-CGH32 in which a loss of one
PARG1 allele was shown. Furthermore, for two addi-
tional cases a deletion of 1p11-p31 and 1p13-p33 was
detected by routine karyotyping (data not shown). A
drastic reduction of gene expression should be the con-
sequence of the observed epigenetic silencing.
Unfortunately, due to shortage of material, RT-PCR
could not be performed on the same cases. However,
array-based genome-wide gene expression profiling
was done on an independent set of MCL cases, demon-
strating a significant down-regulation of PARG1. PARG1
is down-regulated to approximately 30% of control
level. 
In conclusion, PARG1, coding for a RhoGTPase acti-
vation protein, was found to be methylated in all stud-
ied MCL cell lines as well as in all studied primary MCL
samples. Furthermore, a strong down-regulation of
PARG1 was observed in all MCL cases analyzed. Thus,
PARG1 may be a crucial candidate tumor suppressor
gene in the frequently deleted region 1p22.1, satisfying
Knudson’s hypothesis by monoallelic deletion and tran-
scriptional silencing of the other allele. Further investi-
gations are required to define the proportions and func-
tional consequences of genetic and epigenetic mecha-
nisms that may lead to a biallelic knockdown of PARG1
in MCL.
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